Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.

An annual shot to protect against HIV infection has successfully passed an early safety trial, according to research published in The Lancet medical journal. The drug lenacapavir passed a critical Phase I testing trial and now may become a highly-effective and convenient form of HIV prevention.

Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against infection with just a

If future trials go well - now it has passed the first, Phase I, testing hurdle - it could become the longest-acting form of HIV prevention available. Currently, people can take daily pills or sometimes have injections every eight weeks,